PanGIA Liver
Liver Cancer
Pre-clinicalActive
Key Facts
About PanGIA Biotech
PanGIA Biotech is pioneering an AI-driven, multi-fluid diagnostic platform centered on a non-invasive 'True Liquid Biopsy' using urine. The company's PanGIA Analysis System (PAS) applies machine learning to colorimetric biomolecular profiles to detect early-stage cancers with the goal of improving accuracy, accessibility, and patient comfort over traditional methods like blood tests or tissue biopsies. While its lead PanGIA Prostate assay is in use globally for diagnostic research, the company is navigating the path toward FDA approval and commercial scale-up to address the significant global need for better early cancer detection.
View full company profileTherapeutic Areas
Other Liver Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| CY-101 | Cytovation | Phase 1 |
| SA-033 | Double Bond Pharmaceutical | Pre-clinical |
| PRDM2 Target | ARIZ Precision Medicine | Discovery |
| Ad-SGE-REIC + Anti-tumor Agent | Momotaro-Gene | Preclinical/Research |
| Alpha DaRT | Alpha Tau Medical | Not Specified |